Enhanced induction of apoptosis in a radio-resistant bladder tumor cell line by combined treatments with X-rays and wortmannin.
The radiosensitizing effect of wortmannin (WM) treatment during and after irradiation was studied in radioresistant bladder tumor cell lines with normal (MGH-U1 cells) or defective p53 activity (RT112 cells). WM modulated G(2)/M cell cycle arrest induced by higher X-ray doses (10 Gy) in both cell lines, although the alteration was significant only in RT112 cells. The observation suggests that WM activity is independent of p53. Constitutive expression of DNA-PKcs was found to be higher in RT112 cells than in MGH-U1. Treatment with WM enhanced radiation-induced apoptosis significantly in RT112 cells while it had no effect on MGH-U1 cells. Although a variety of PI3-kinases and PI3-K like kinases (including ATM) could be inhibited by WM, our observation of increased early lethality by WM treatment in RT112 is in agreement with previous results. They suggest that the WM-dependent radiosensitization of RT112 is a direct consequence of the inhibition of DNA-PK, resulting in the inhibition of DSB repair in the fast component. This early effect in the p53 deficient cell line could also indicate that processes other than apoptosis may contribute to the increased radiosensitization. In our opinion, the expression level of DNA-PKcs in human tumor cells may be a good predictor for the success of DNA-PKcs inhibitors when used as radiosensitizers.
Ortiz
Trinidad
T
Departamento de Biología Celular, Facultad de Biologia, Universidad de Sevilla Avda. Reina Mercedes s/n, 41012 Sevilla, Spain. salles@us.es
Burguillos
Miguel Angel
MA
López-Lluch
Guillermo
G
Navas
Plácido
P
Herrador
Miguel
M
González
Isabel
I
Piñero
Joaquín
J
D000730:Androstadienes / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects* / Q000528:radiation effects*; D045744:Cell Line, Tumor; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D011829:Radiation Dosage; D011836:Radiation Tolerance / Q000187:drug effects*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000503:physiopathology*; D000077191:Wortmannin; D014965:X-Rays
D000730:Androstadienes; D011838:Radiation-Sensitizing Agents; D000077191:Wortmannin
Radiother Oncol. 2007 Jun;83(3):296-303
17521756
Mutat Res. 2000 Sep 20;453(1):5-15
11006407
Radiat Res. 1993 Jun;134(3):349-54
8316628
Int J Oncol. 2006 Nov;29(5):1111-7
17016641
J Clin Invest. 1996 Jun 1;97(11):2403-4
8647929
Radiother Oncol. 1984 Dec;2(4):317-23
6395213
Br J Cancer. 2000 Oct;83(8):1084-95
10993658
J Biol Chem. 2004 Apr 9;279(15):15269-73
14752107
Int J Oncol. 2004 Jan;24(1):169-75
14654954
Br J Cancer. 1999 Nov;81(6):959-65
10576651
Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1035-40
8083072
Cell. 1993 Jan 15;72(1):131-42
8422676
Cancer Res. 1998 Oct 1;58(19):4375-82
9766667
Oncol Rep. 2002 Jul-Aug;9(4):859-62
12066222
Tohoku J Exp Med. 1977 Feb;121(2):157-64
847742
Int J Radiat Biol. 2004 Aug;80(8):593-605
15370971
Cancer Treat Rev. 2005 Dec;31(8):603-17
16298073
Nature. 1998 Aug 13;394(6694):700-4
9716137
Br J Cancer. 1996 Mar;73(5):581-8
8605090
Mol Cell Biol. 1996 Apr;16(4):1722-33
8657148
Eur J Cancer. 1999 Jan;35(1):111-6
10211098
Cell Death Differ. 1998 Aug;5(8):687-93
10200524
EMBO J. 2002 Jun 17;21(12):3000-8
12065413
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1584-8
10677503
Oncogene. 2002 Aug 29;21(38):5868-76
12185586
Curr Biol. 2001 Feb 20;11(4):R121-4
11250164
J Biol Chem. 2003 Oct 24;278(43):41631-5
12917393
Mol Cells. 2002 Apr 30;13(2):159-66
12018836
J Radiat Res. 2003 Jun;44(2):151-9
13678345
Radiat Res. 2003 Nov;160(5):559-67
14565826
Int J Oncol. 2003 Nov;23(5):1431-7
14532987
Cancer Res. 2006 May 15;66(10):5354-62
16707462
Radiat Res. 2003 Oct;160(4):467-77
12968928
Cancer Lett. 2000 Dec 20;161(2):141-7
11090962
Cancer Res. 1986 Jul;46(7):3630-6
3708594
Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1394-7
1996340